UNITY Biotechnology to Participate in Upcoming March Investor Conferences
Unity Biotechnology [NASDAQ: UBX] announced participation in two virtual investor conferences in March 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Unity Biotechnology [NASDAQ: UBX] announced participation in two virtual investor conferences in March 2021. The Cowen 41st Annual Healthcare Conference will take place on March 3 at 1:20 p.m. ET, followed by the 33rd Annual ROTH Conference on March 15 at 4:00 p.m. ET. A live audio webcast of both presentations will be accessible on Unity's website, with replays available for 90 days after each event. Unity focuses on developing therapeutics aimed at slowing, halting, or reversing diseases of aging, particularly targeting senescent cells to benefit age-related conditions.
Details
News Market Reaction – UBX
The recorded move for UBX in the trading session of this news was +11.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will participate in the following upcoming March virtual investor conferences:
Cowen 41st Annual Healthcare Conference
Date: March 3, 2021
Presentation Time: 1:20 p.m. ET
33rd Annual ROTH Conference
Date: March 15, 2021
Presentation Time: 4:00 p.m. ET
A live audio webcast of the presentations will be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following each event.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.